User Fees

The FDA Reauthorization Act of 2017 reauthorized the pharmaceutical, medical device, generic drug, and biosimilar user fee agreements until 2022. The Alliance played an important role in the input process for the legislation, including enhancing regulatory science and expediting drug development, hiring of FDA staff, and patient focused drug development (PFDD).